OPNT - OPNT STOCK NEWS

Opiant Pharmaceuticals (NASDAQ: OPNT) has received CFIUS clearance for its merger with Indivior PLC, marking the final regulatory approval needed. The acquisition involves Indivior acquiring Opiant’s outstanding shares at $20.00 per share in cash, along with contingent value rights allowing for additional payments of up to $8.00 per share. Opiant’s stockholders will vote on the merger on March 1, 2023, with completion anticipated in Q1 2023. This strategic merger aims to enhance Opiant's capabilities in combating addiction and drug overdoses.

Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced the expiration of the waiting period under the Hart-Scott-Rodino Act regarding its acquisition by Indivior PLC. The waiting period ended on February 2, 2023, with no action from the Federal Trade Commission. The acquisition requires approval from Opiant stockholders and other regulatory conditions. Opiant's shareholders will vote on the merger on March 1, 2023, with Indivior offering $20.00 per share in cash and potential additional payments of up to $8.00 per share. Opiant's Board of Directors recommends a “FOR” vote on the acquisition.

Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) announced that the FDA has accepted its New Drug Application (NDA) for OPNT003, a nasal formulation of nalmefene aimed at treating opioid overdose. This NDA received Priority Review status, shortening the review timeline to six months, with a PDUFA date set for May 22, 2023. This is a crucial step towards potential approval and market launch, addressing the opioid crisis in the U.S. which saw over 81,000 overdose deaths in the past year. Opiant has received significant funding, including up to $10.8 million from BARDA, to support OPNT003's development.

Opiant Pharmaceuticals (NASDAQ: OPNT) announced the submission of its rolling New Drug Application (NDA) for OPNT003, a nasal formulation of nalmefene, to the FDA for treating opioid overdose. CEO Roger Crystal expressed optimism that OPNT003 could provide vital support for first responders amid the opioid crisis, which led to over 81,000 deaths in the U.S. in 2022. The NDA is backed by comprehensive pharmacokinetic and pharmacodynamic studies. FDA's decision on the NDA acceptance is anticipated in February 2023. Funding from BARDA and NIDA significantly supported the development process.

Opiant Pharmaceuticals (NASDAQ: OPNT) reported a significant revenue decline for Q3 2022 at $0.2 million, down from $16.3 million in Q3 2021, due to the termination of a license agreement with Emergent Biosolutions. A one-time cash settlement of $25 million from Emergent was received, enhancing financial flexibility. The net loss for Q3 2022 was approximately $10 million, compared to a net income of $3.4 million in Q3 2021. As of September 30, 2022, the company holds $35.4 million in cash and cash equivalents. Opiant is progressing towards the NDA submission for OPNT003 in Q4 2022.

Indivior has announced its acquisition of Opiant Pharmaceuticals for a total value of $28.00 per share, which includes an upfront cash payment of $20.00 and contingent value rights (CVRs) potentially worth up to $8.00 based on revenue thresholds for OPNT003. This deal represents a premium of 111% over Opiant's closing share price prior to the announcement. The acquisition is expected to enhance Indivior's portfolio in addiction therapies and is pending regulatory and shareholder approvals, with a completion anticipated in Q1 2023.

Indivior announced its acquisition of Opiant Pharmaceuticals for $20 per share, totaling approximately $145 million, with additional contingent payments of up to $8 per share depending on revenue milestones of OPNT003, Opiant's opioid overdose treatment. This strategic acquisition aims to enhance Indivior's position in addiction treatment and is expected to be accretive to earnings after the second year post-launch of OPNT003, which could generate annual revenues of $150-$250 million. The transaction is subject to regulatory approvals and is anticipated to close in Q1 2023.

Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its third-quarter financial results on November 14, 2022, after market close. A conference call will follow at 4:30 PM ET, accessible via U.S. and international lines. Opiant specializes in developing medicines for addiction and overdose treatment, including the NARCAN® Nasal Spray. The company aims to build a robust portfolio in this critical healthcare area, emphasizing its commitment to combating substance-related emergencies.

Opiant Pharmaceuticals (NASDAQ: OPNT) announced the successful enrollment of the last patient in the Phase 2 clinical trial of OPNT002, a nasal naltrexone treatment for Alcohol Use Disorder (AUD). The trial, initiated in January 2022, involves 300 patients and uses a Sequential Parallel Comparison Study Design. The last patient is expected to complete the study by early 2023, with top-line results anticipated mid-year. This development is a significant step towards providing alternative treatment options for AUD, a major public health issue.